94 related articles for article (PubMed ID: 23073055)
1. Using ligands to target cancer cells.
Farokhzad OC
Clin Adv Hematol Oncol; 2012 Aug; 10(8):543-4. PubMed ID: 23073055
[No Abstract] [Full Text] [Related]
2. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
4. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
5. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
6. 2-5A ligands--a new concept for the treatment of prostate cancer.
Cramer H; Okicki JR; Rho T; Wang X; Silverman RH; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1471-7. PubMed ID: 18066809
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.
Korang-Yeboah M; Patel D; Morton D; Sharma P; Gorantla Y; Joshi J; Nagappan P; Pallaniappan R; Chaudhary J
Oncotarget; 2016 Oct; 7(42):68072-68085. PubMed ID: 27487149
[TBL] [Abstract][Full Text] [Related]
9. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Pfestroff A; Luster M; Jilg CA; Olbert PJ; Ohlmann CH; Lassmann M; Maecke HR; Ezziddin S; Bodei L;
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1971-5. PubMed ID: 26373947
[No Abstract] [Full Text] [Related]
10. Programing Assembling/Releasing Multifunctional miRNA Nanomedicine to Treat Prostate Cancer.
Ma D; Liu H; Zhao P; Ye L; Zou H; Zhao X; Dai H; Kong X; Liu P
ACS Appl Mater Interfaces; 2020 Feb; 12(8):9032-9040. PubMed ID: 31986004
[TBL] [Abstract][Full Text] [Related]
11. Cancer nanomedicine: from targeted delivery to combination therapy.
Xu X; Ho W; Zhang X; Bertrand N; Farokhzad O
Trends Mol Med; 2015 Apr; 21(4):223-32. PubMed ID: 25656384
[TBL] [Abstract][Full Text] [Related]
12. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
[TBL] [Abstract][Full Text] [Related]
13. Antibody recruiting small molecules: a new option for prostate tumor therapy by PSMA targeting.
Küchenthal CH; Maison W
Chembiochem; 2010 May; 11(8):1052-4. PubMed ID: 20432428
[No Abstract] [Full Text] [Related]
14. Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
Jiang S; Gong X; Zhao X; Zu Y
Drug Deliv; 2015 Feb; 22(2):206-13. PubMed ID: 24471890
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer target 'moveable'.
Foubister V
Drug Discov Today; 2005 Jul; 10(14):951-2. PubMed ID: 16023050
[No Abstract] [Full Text] [Related]
16. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M
J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710
[TBL] [Abstract][Full Text] [Related]
17. Zinc-ion-mediated self-assembly of forky peptides for prostate cancer-specific drug delivery.
Tao M; Xu K; He S; Li H; Zhang L; Luo X; Zhong W
Chem Commun (Camb); 2018 May; 54(37):4673-4676. PubMed ID: 29675529
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle therapeutics: a personal perspective.
McNeil SE
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):264-71. PubMed ID: 20049796
[TBL] [Abstract][Full Text] [Related]
19. Nanoformulation of natural products for prevention and therapy of prostate cancer.
Sanna V; Siddiqui IA; Sechi M; Mukhtar H
Cancer Lett; 2013 Jun; 334(1):142-51. PubMed ID: 23201598
[TBL] [Abstract][Full Text] [Related]
20. A hydrophobic starch polymer for nanoparticle-mediated delivery of docetaxel.
Dandekar P; Jain R; Stauner T; Loretz B; Koch M; Wenz G; Lehr CM
Macromol Biosci; 2012 Feb; 12(2):184-94. PubMed ID: 22127828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
